Oral GLP-1 Composition Using SNAC Salt for Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human GLP-1 and its analogues have low oral bioavailability, necessitating the development of optimized pharmaceutical compositions for effective oral administration.
Innovation Solution
A composition comprising a GLP-1 agonist, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), and a hydrotrope, which enhances solubility and absorption, allowing for fast and efficient uptake of the active pharmaceutical ingredient.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If GLP-1 agonist is administered orally, then it can be given via a convenient route, but bioavailability is very low and therapeutic plasma concentrations cannot be achieved
Solution Approach 1:
The patent introduces SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) as an absorption enhancer that mediates between the GLP-1 agonist and the gastrointestinal tract. SNAC facilitates paracellular transport of the peptide across the intestinal epithelium, enabling oral bioavailability without requiring parenteral administration
Solution Approach 2:
The patent optimizes specific parameters including the SNAC to GLP-1 agonist weight ratio (5:1 to 200:1), pH of the composition (5.0 to 7.5), and amount of excipients to maximize absorption. These parameter adjustments transform the poorly absorbed oral formulation into one achieving therapeutic plasma concentrations
2Reliability
If GLP-1 agonist is formulated with absorption enhancers, then oral bioavailability improves, but the formulation complexity increases
Solution Approach 1:
The patent applies absorption enhancement locally at the gastrointestinal absorption site rather than systemically. SNAC acts specifically in the gut to facilitate peptide transport, while other components address local formulation needs such as solubility and stability in the gastrointestinal environment
Solution Approach 2:
The patent creates a composite oral formulation combining GLP-1 agonist, SNAC absorption enhancer, hydrotrope for solubility enhancement, and specific excipients. This composite approach integrates multiple functional components into a single oral dosage form that achieves bioavailability without requiring complex delivery devices
3Ease of operation
If GLP-1 agonist is administered orally, then convenient dosing is achieved, but rapid degradation in the gastrointestinal system occurs
Solution Approach 1:
The patent incorporates stabilizing excipients and optimizes formulation pH before administration to protect the GLP-1 agonist from degradation. The hydrotrope and buffer system are pre-configured to maintain peptide stability throughout the gastrointestinal transit, preventing rapid breakdown before absorption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves accelerated absorption of GLP-1 agonists within 15-30 minutes, significantly improving exposure and therapeutic efficacy.
Implementation Method 1
a hydrotrope, wherein the hydrotrope is capable of increasing the solubility of SNAC at least 2-fold
Data Source
AI summary
The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.